Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here


Payment Information We Accept Visa, Mastercard, American Express and Discover


By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

Novo Partners with Broad Institute of MIT and Harvard for T2DM; Viking Initiates Ph2 Dual Agonist Obesity Trial; Cytokinetics Initiates Ph3 Aficamten Trial in Non-Obstructive HCM

Here is a brief preview of this blast: Three cardiometabolic-related news items have been observed: The Broad Institute of MIT and Harvard announced a research partnership with Novo Nordisk to identify drug targets for T2DM and genetic roots of cardiac fibrosis (view press release); Viking Therapeutics initiated a Ph2 trial evaluating the company’s SC QW GLP-1 + GIP dual agonist, VK2735, in obese and overweight patients (view press release); and Cytokinetics initiated a pivotal Ph3 trial of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM; view press release). Below, FENIX provides highlights and insights into the respective news items.

About The Author

Matthew Maryniak

President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.